Login to Your Account



Micromet, Serono Enter Cancer Drug Deal Worth Up To $148M

By Karen Pihl-Carey


Wednesday, December 8, 2004
In a deal just shy of $150 million, Micromet AG partnered with Serono SA its Phase II monoclonal antibody, MT201, designed to treat prostate and metastatic breast cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription